Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (51001)	7/26/2019 3:19:48 PM
From: quidditch	Respond to of 52153

Further to patents/moat questions (and of course ACST is in the convo): seekingalpha.com regulations.gov

To: quidditch who wrote (51001)	7/27/2019 2:51:42 PM
From: Biomaven	1 Recommendation Recommended By quidditch Read Replies (1) \| Respond to of 52153

>>I'm aware of the Yee comments on EPA tail once off patent, is this a correct analysis, assuming as it does patentability? This doesn't assume patentability. The key is the brand will have significant penetration because you can't trust the lookalikes once it goes OTC (as it will at some point).